- Home
- Equipment
- usa california
- oncogene
Show results for
Refine by
Oncogene Equipment Supplied In Usa California
7 equipment items found
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
RAS is one of the most well-known oncogenic drivers, with approximately 30% of all cancers being driven by RAS mutations, including large proportions of lung, colorectal and pancreatic tumors. BridgeBio’s approach to RAS cancers encompasses multiple “shots on goal” that target both KRAS mutant tumors and those in which RAS activates PI3Ka. ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Thus far, Sorrento has successfully identified fully human antibodies against over 100 clinically-relevant high-impact oncogenic targets, including PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, and ...
Manufactured by:Biocept based inSan Diego, CALIFORNIA (USA)
Biocept’s Target Selector™ molecular assay kits detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies. The EGFR pathway can include mutations that are among the most frequently evaluated biomarkers for lung ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
Chromosomal translocations found in leukemias and lymphomas either fuse enhancer/promoter regions of one gene to another, causing aberrant expression, or by fusing a part of one gene to that of another, resulting in disruption of the normal function of the native genes involved in the translocation, or by gaining new oncogenic functions that promote proliferation and ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Stephen Neidle and his group at UCL, the G4 binding concept is derived from 30+ years in nucleic acid research, including that of G4s, which are higher order DNA and RNA structures formed by sequences containing guanine-rich repeats. G4s are overrepresented in telomeres as well as promoter sequences and untranslated regions of many oncogenes. Their prevalence is therefore ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Tempus xE (version 2) is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. Clinical sequencing is performed to 500x depth of coverage for tumor specimens and 150x for normal specimens for the clinically enhanced regions (648 genes). Non-enhanced regions are performed at ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...